Letters by company
Kkr-p-d
3 letters discussing KKR-P-D. Everything written about it on this site is on its ticker page.
- Dodge & Cox Stock Fund Stock Fund Investment Commentary Dodge & Cox Stock Fund initiated positions in Visa, Thermo Fisher Scientific, and KKR after AI-disruption concerns and macro fears pushed their valuations lower. The fund retained conviction in Fidelity National Information Services, Fiserv, and Charter Communications, arguing that their valuation declines overstate risks, while its technology underweight hurt relative results. Second Quarter +5.6% KKR-P-D TMO $231BV $693BCHTR $18B
- Greenhaven Road Capital Q4 2025 Greenhaven Road Capital groups Lifecore and Vistry as “Bamboo Trees,” where operational transformations and capacity or partnership-model progress have yet to be reflected in valuations. It argues that fears around AI disruption, litigation, fundraising and credit are mispriced at PAR, Cellebrite, Burford and KKR, while Hagerty benefits from State Farm onboarding and marketplace growth. Q4 2025 -2.0% BUR $946MCLBT $2.9BHGTY $4.6BKKR-P-D
- Greenhaven Road Capital Main Fund Q2 Greenhaven Road Capital is reducing concentration and adding catalyst-driven positions while retaining its emphasis on differentiated research. It argues that Burford’s protein litigation, Hagerty’s insurer partnerships, Cellebrite’s Genesis rollout, Lifecore’s capacity sales and Kingsway’s search-model buildout can close gaps between market expectations and business value. Q2 2026 +11.0% BUR $946MCLBT $2.9BHGTY $4.6BANAB $1.7B
